Literature DB >> 10428284

Laryngeal tuberculosis in renal transplant recipients.

V Jha1, H S Kohli, K Sud, K L Gupta, M Minz, K Joshi, V Sakhuja.   

Abstract

BACKGROUND: Tuberculosis is the most common non-pyogenic infection encountered among renal transplant recipients in India. Although the lung is the most common site of involvement, a number of extrapulmonary organs can be involved. There is often a delay in diagnosis and institution of effective chemotherapy when there is an unusual site of involvement. METHODS AND
RESULTS: We report two renal transplant recipients with laryngeal tuberculosis who presented with prolonged hoarseness of voice and painful dysphagia. Acid-fast bacilli were demonstrated on laryngeal biopsy and smear. Fever and pulmonary involvement were seen in only one patient. This is the first report of laryngeal tuberculosis in renal transplant recipients.
CONCLUSIONS: Laryngeal tuberculosis should be suspected in renal transplant recipients who develop hoarseness of voice and odynophagia. Demonstration of acid-fast bacilli on biopsy or smear obtained by direct laryngoscopy helps in determining the diagnosis.

Entities:  

Mesh:

Year:  1999        PMID: 10428284     DOI: 10.1097/00007890-199907150-00028

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  3 in total

Review 1.  Non-viral infections in children after renal transplantation.

Authors:  Francesca Mencarelli; Stephen D Marks
Journal:  Pediatr Nephrol       Date:  2012-02-09       Impact factor: 3.714

2.  Tubercular constrictive pericarditis after renal transplantation.

Authors:  A Anitha; V Siddini; H S Ballal
Journal:  Indian J Nephrol       Date:  2015 Mar-Apr

Review 3.  Laryngeal tuberculosis in renal transplant recipients: A case report and review of the literature.

Authors:  Fabrizio Cialente; Michele Grasso; Massimo Ralli; Marco De Vincentiis; Antonio Minni; Griselda Agolli; Michele Dello Spedale Venti; Mara Riminucci; Alessandro Corsi; Antonio Greco
Journal:  Bosn J Basic Med Sci       Date:  2020-08-03       Impact factor: 3.363

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.